DOFETILIDE PACKAGE INSERT EPUB

Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.

Author: Najind Akinotilar
Country: Libya
Language: English (Spanish)
Genre: Education
Published (Last): 6 August 2018
Pages: 224
PDF File Size: 20.9 Mb
ePub File Size: 5.84 Mb
ISBN: 725-5-43032-799-7
Downloads: 22160
Price: Free* [*Free Regsitration Required]
Uploader: Dougis

The authors dofetilide package insert reported that they have no relationships relevant to the contents of this paper to disclose. Pacing Clin Electrophysiol The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Indeed, the most common cause of acquired QT prolongation is exposure to QT-prolonging drugs, which act by blocking hERG-encoded potassium channels 24— Concomitant use of other QT-prolonging drugs was associated with discontinuation of dofetilide.

However, the discontinuation rate of dofetilide package insert is higher in cohort studies such dofetilide package insert ours. Conclusions These data indicate that the incidence of dofetilide discontinuation because of QT prolongation or VT in a real-world setting is remarkably higher than that reported in clinical trials.

Dofetilide Capsules

Dofetilide package insert who did not revert to sinus rhythm after 5 doses of dofetilide underwent electrical cardioversion before discharge. Little is known about the incidence and risk factors for discontinuation of dofetilide in the real world, where patients are usually sicker than dofetilide package insert enrolled in clinical trials 18—20 and might be taking other QT-prolonging medications Study limitations Limitations of this study include the following: To our knowledge, this is the one of the few studies study assessing the incidence and predictors of discontinuation of dofetilide in a real-world, inpatient setting.

Am J Med Concomitant use of other QT-prolonging drugs dofetilide package insert associated with discontinuation of dofetilide. These data indicate that the incidence of dofetilide discontinuation because of QT prolongation or VT in a real-world setting is remarkably higher than that reported in clinical trials. Am Heart J Also, some additional information can be gleaned from retrospective observational studies published for other reasons.

The dofetilide package insert of dofetilide discontinuation remained high in the subgroup of patients who had normal QTc at baseline and were not taking concomitant hydrochlorothiazide. Skip to main content.

Download high-res image 99KB Download full-size image. Conclusions The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials. Recommended articles Citing articles 0. Outcomes of Citalopram dose-risk mitigation in a veteran population.

Further, dofetilide is the dofetilide package insert antiarrhythmic drug, besides amiodarone, that is approved for use in patients with severe left ventricular systolic dysfunction 15, Med Clin Dofetilise Am QTc corrected QT interval. American College of Cardiology Foundation. Although it is ideal to docetilide or replace dofetilide package insert medications with alternatives when starting dofetilide, it is not always possible.

Objectives The purpose of this study was to determine the incidence and correlates of QT prolongation or ventricular tachycardia VT resulting in discontinuation of dofetilide in a real-world setting. Conclusions Inseet incidence of QT prolongation or VT that lead dofetilide package insert discontinuation of dofetilide is remarkably higher in the real-world setting than in clinical trials.

As such, this study fills an important gap in our knowledge. The purpose of this study dofetilide package insert to determine the incidence and correlates of QT prolongation or ventricular tachycardia VT resulting in discontinuation of dofetilide in a real-world setting.

Dofetilide (Tikosyn) | Pharmacy

Footnotes The authors have reported that they have no relationships relevant to the contents of this paper to disclose. View inline View popup. Circ Arrhythm Electrophysiol 8: Graphical abstract Download high-res image 99KB Download full-size image.

However, neither study examined the factors associated with the discontinuation of dofetilide None of the patients had worsening fofetilide renal function during the index hospitalization. The majority of the concomitant QT-prolonging drugs in this study were antidepressants. Am J Psychiatry[E-pub ahead of print]. Insrt you for your interest in spreading the word about JACC: Am J Cardiol Dofetilide was started during a h inpatient hospitalization per standard protocol You are viewing the most recent version of this article.

The 2 dofetilide package insert groups were compared using the chi-square test for categorical variables and the Student t test for continuous variables. The incidence of QT prolongation or VT that lead to discontinuation of dofetilide package insert is remarkably higher in the real-world dofetilide package insert than in clinical trials.

FDA Internet Site Error

Abbreviations and Acronyms AF dofetilide package insert fibrillation. Serum electrolytes, including potassium and magnesium, were monitored daily during the hospital stay and corrected as needed.

These results suggest that the incidence of discontinuation of dofetilide because packave adverse events is much higher in a real-world setting than has been reported in dofetilide package insert trials.